{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:47:36Z","timestamp":1773208056218,"version":"3.50.1"},"reference-count":31,"publisher":"Scientific Scholar","content-domain":{"domain":["jpalliativecare.com"],"crossmark-restriction":true},"short-container-title":["IJPC"],"abstract":"\nObjectives:<\/jats:title>\nIn India, cervical cancer is the most common cancer among women and makes up for up to 29% of all registered cancer in females. Cancer-related pain is one of the major distressing symptoms for all cancer patients. Pain is characterised as somatic or neuropathic, and the total pain experience is often mixed. Conventional opioids are the backbone of analgesic treatment but are most often not sufficient in alleviating neuropathic pain, common in cervical cancer. Accumulating evidence of the advantage of methadone compared to conventional opioids, due to agonist action at both \u03bc and q opioid receptors, N-methyl-D-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamines has been demonstrated. We hypothesised that, with these properties\u2019, methadone might be a good option for the treatment of neuropathic pain in patients with cervical cancer.<\/jats:p>\n<\/jats:sec>\n\nMaterial and Methods:<\/jats:title>\nPatients with cervical cancer stages ll-lll were enrolled in this randomized controlled trial. A comparison was made between methadone versus immediate release morphine (IR morphine), with increasing doses until pain was controlled. Inclusion-period was from October 3rd<\/jats:sup> to December 31st<\/jats:sup> 2020, and the total patient-study period was 12 weeks. Pain intensity was assessed according to the Numeric Rating Scale (NRS) and Douleur Neuropathique (DN4). The primary objective was to determine whether methadone was clinically superior versus noninferior to morphine as an analgesic for the treatment of cancer related neuropathic pain in women with cervical cancer.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nA total of 85 women were included; five withdrew and six died during the study period, leaving 74 patients completing the study. All participants showed a reduction in mean values of NRS and DN4 from the time of inclusion and to the end of the study period, for IR morphine and methadone 8.4\u20132.7 and 8.6\u20131.5, respectively (P<\/jats:italic> < 0.001). The DN4 score mean reduction for Morphine and Methadone were 6.12\u20131.37 and 6.05\u20130, respectively (P<\/jats:italic> < 0.001). Side effects were more common in the group of patients receiving IR morphine compared to the patients treated with methadone.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nWe found that Methadone had a superior analgesic effect with good overall tolerability compared with morphine as a first-line strong opioid for the management of cancer-related neuropathic pain.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijpc_58_2022","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T15:04:53Z","timestamp":1685631893000},"page":"200-206","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral Methadone versus Morphine IR for Patients with Cervical Cancer and Neuropathic Pain: A Prospective Randomised Controlled Trial"],"prefix":"10.25259","volume":"29","author":[{"given":"Aruna","family":"Adumala","sequence":"first","affiliation":[{"name":"Department of Pain and Palliative Medicine, MNJ Institute of Oncology and RCC, Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Palat","sequence":"additional","affiliation":[{"name":"Department of Pain and Palliative Medicine, MNJ Institute of Oncology and RCC, Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Vajjala","sequence":"additional","affiliation":[{"name":"Pain Relief and Palliative Care Society, Hyderabad, Telangana, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brun","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Oncology, Lund University and Sk\u00e5nes University Hospital, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Segerlantz","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Institute for Palliative Care, Faculty of Medicine, Lund University, Lund, Sweden,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"10.25259\/IJPC_58_2022\/ref-1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11916-011-0190-6","article-title":"Psychosocial issues in cancer pain","volume":"15","author":"Porter","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"10.25259\/IJPC_58_2022\/ref-2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00497-9","article-title":"Cancer pain and psychosocial factors: A critical review of the literature","volume":"24","author":"Zaza","year":"2002","journal-title":"J Pain Symptom Manag"},{"key":"10.25259\/IJPC_58_2022\/ref-3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00520-018-4471-z","article-title":"Optimizing cancer pain management in resource-limited settings","volume":"27","author":"Ahmedzai","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_58_2022\/ref-4","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1172\/JCI42843","article-title":"Nociceptors: The sensors of the pain pathway","volume":"120","author":"Dubin","year":"2010","journal-title":"J Clin Invest"},{"key":"10.25259\/IJPC_58_2022\/ref-5","first-page":"14","article-title":"Cancer Pain Relief with a Guide to Opioid Availability: Report from a WHO Expert Committee","year":"1996","edition":"2nd ed"},{"key":"10.25259\/IJPC_58_2022\/ref-6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/papr.12291","article-title":"Neuropathic pain components in patients with cancer: Prevalence, treatment, and interference with daily activities","volume":"16","author":"Oosterling","year":"2016","journal-title":"Pain Pract"},{"key":"10.25259\/IJPC_58_2022\/ref-8","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1007\/s00520-017-3806-5","article-title":"Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients","volume":"25","author":"Oh","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_58_2022\/ref-9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","article-title":"Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)","volume":"114","author":"Bouhassira","year":"2005","journal-title":"Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jpain.2009.09.014","article-title":"Translation to portuguese and validation of the douleur neuropathique 4 questionnaire","volume":"11","author":"Santos","year":"2010","journal-title":"J Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/0971-5851.195751","article-title":"Burden of cervical cancer and role of screening in India","volume":"37","author":"Bobdey","year":"2016","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.25259\/IJPC_58_2022\/ref-12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00018-019-03047-y","article-title":"Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic pain","volume":"76","author":"Deng","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.25259\/IJPC_58_2022\/ref-13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/eujp.1999.0154","article-title":"Wind-up and the NMDA receptor complex from a clinical perspective","volume":"4","author":"Eide","year":"2000","journal-title":"Eur J Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s005200000180","article-title":"Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration","volume":"9","author":"Davis","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_58_2022\/ref-15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","article-title":"Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review","volume":"4","author":"McNicol","year":"2003","journal-title":"J Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-16","doi-asserted-by":"publisher","first-page":"CD003971","DOI":"10.1002\/14651858.CD003971.pub4","article-title":"Methadone for cancer pain","volume":"2017","author":"Nicholson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.25259\/IJPC_58_2022\/ref-17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jpainsymman.2017.10.017","article-title":"Methadone as a first-line opioid in cancer pain management: A systematic review","volume":"55","author":"Mercadante","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"10.25259\/IJPC_58_2022\/ref-18","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.4103\/IJPC.IJPC_186_17","article-title":"Practical guide for using methadone in pain and palliative care practice","volume":"24","author":"Palat","year":"2018","journal-title":"Indian J Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.25259\/IJPC_383_20","article-title":"The introduction and experiences of methadone for treatment of cancer pain at a low-resource Governmental cancer center in India","volume":"27","author":"Palat","year":"2021","journal-title":"Indian J Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.25259\/IJPC_383_20","article-title":"The introduction and experiences of methadone for treatment of cancer pain at a low-resource governmental cancer center in India","volume":"27","author":"Palat","year":"2021","journal-title":"Indian J Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.25259\/IJPC_383_20","article-title":"The use of Methadone in adult patients with cancer-pain at a governmental cancer centre in India","volume":"27","author":"Palat","year":"2021","journal-title":"Indian J Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/24740527.2019.1660575","article-title":"Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment","volume":"3","author":"Lynch","year":"2019","journal-title":"Can J Pain"},{"key":"10.25259\/IJPC_58_2022\/ref-23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-684X-7-10","article-title":"A reliability and validity study of the palliative performance scale","volume":"7","author":"Ho","year":"2008","journal-title":"BMC Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-24","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1089\/jpm.2018.0141","article-title":"Using the palliative performance scale to estimate survival for patients at the end of life: A systematic review of the literature","volume":"21","author":"Baik","year":"2018","journal-title":"J Palliat Med"},{"key":"10.25259\/IJPC_58_2022\/ref-25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/082585979601200102","article-title":"Palliative performance scale (PPS): A new tool","volume":"12","author":"Anderson","year":"1996","journal-title":"J Palliat Care"},{"key":"10.25259\/IJPC_58_2022\/ref-26","first-page":"208","article-title":"Availability and utilization of opioids for pain management: Global issues","volume":"14","author":"Manjiani","year":"2014","journal-title":"Ochsner J"},{"key":"10.25259\/IJPC_58_2022\/ref-27","article-title":"Global Access to Pain Relief Evidence for Action","author":"Goltz","year":"2020","journal-title":"European Society for Medical Oncology"},{"key":"10.25259\/IJPC_58_2022\/ref-28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/15360288.2010.536307","article-title":"A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels","volume":"25","author":"Seya","year":"2011","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.25259\/IJPC_58_2022\/ref-29","article-title":"Model List of Essential Medicines","author":"World Health Organization","year":"2019"},{"key":"10.25259\/IJPC_58_2022\/ref-30","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1007\/s00520-016-3191-5","article-title":"Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit","volume":"24","author":"Peirano","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.25259\/IJPC_58_2022\/ref-31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/jpm.2017.0157","article-title":"Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment","volume":"21","author":"F\u00fcrst","year":"2018","journal-title":"J Palliat Med"}],"container-title":["Indian Journal of Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jpalliativecare.com\/oral-methadone-versus-morphine-ir-for-patients-with-cervical-cancer-and-neuropathic-pain-a-prospective-randomised-controlled-trial\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jpalliativecare.com\/oral-methadone-versus-morphine-ir-for-patients-with-cervical-cancer-and-neuropathic-pain-a-prospective-randomised-controlled-trial\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T15:04:57Z","timestamp":1685631897000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpalliativecare.com\/oral-methadone-versus-morphine-ir-for-patients-with-cervical-cancer-and-neuropathic-pain-a-prospective-randomised-controlled-trial\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":31,"alternative-id":["10.25259\/IJPC_58_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijpc_58_2022","relation":{},"ISSN":["1998-3735","0973-1075"],"issn-type":[{"value":"1998-3735","type":"electronic"},{"value":"0973-1075","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"200"}}